Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion.
New Strong Sell Stocks for January 3rd
AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.
New Strong Sell Stocks for December 5th
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.
New Strong Sell Stocks for November 22nd
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.
Q3 2024 Earnings: Hold Akebia Therapeutics
Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expanding its market through partnerships and trials, addressing unmet needs in anemia treatment for CKD patients, and exploring label expansion. Risks include potential competition post-2025 due to patent expiration for Auryxia, but current limited competition and strong brand recognition mitigate this.
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.
Here's Why You Should Consider Buying Akebia (AKBA) Stock
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - President and Chief Executive Officer Nicholas Grund - Senior Vice President, Chief Commercial Officer Erik Ostrowski - Senior Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Thank you for standing by.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago.
